January 29, 2018 / 1:35 PM / 4 months ago

BRIEF-Sorrento Says China Oncology Focus Received Approval In China To Begin Clinical Trials For ZKAB001

Jan 29 (Reuters) - Sorrento Therapeutics Inc:

* CHINA ONCOLOGY FOCUS LIMITED RECEIVES APPROVAL BY CHINESE AUTHORITIES TO BEGIN CLINICAL TRIALS IN THREE SEPARATE CANCER INDICATIONS USING SORRENTO’S ANTI-PD-L1 MONOCLONAL ANTIBODY

* SORRENTO THERAPEUTICS - ‍CLINICAL DATA FROM STUDIES COULD BE AVAILABLE BY END OF YEAR 2019​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below